HRP20210361T1 - Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja - Google Patents
Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja Download PDFInfo
- Publication number
- HRP20210361T1 HRP20210361T1 HRP20210361TT HRP20210361T HRP20210361T1 HR P20210361 T1 HRP20210361 T1 HR P20210361T1 HR P20210361T T HRP20210361T T HR P20210361TT HR P20210361 T HRP20210361 T HR P20210361T HR P20210361 T1 HRP20210361 T1 HR P20210361T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical compound
- neurodegenerative disorder
- patient
- use according
- progression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928622P | 2014-01-17 | 2014-01-17 | |
| PCT/US2015/011798 WO2015109215A1 (en) | 2014-01-17 | 2015-01-16 | The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs |
| EP15737329.1A EP3094616B1 (en) | 2014-01-17 | 2015-01-16 | The use of glyceryl tribenzoate containing composition in neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210361T1 true HRP20210361T1 (hr) | 2021-04-16 |
Family
ID=53543490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210361TT HRP20210361T1 (hr) | 2014-01-17 | 2015-01-16 | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9968582B2 (enExample) |
| EP (1) | EP3094616B1 (enExample) |
| JP (2) | JP6836905B2 (enExample) |
| CA (1) | CA2936548C (enExample) |
| CY (1) | CY1124115T1 (enExample) |
| DK (1) | DK3094616T3 (enExample) |
| ES (1) | ES2853974T3 (enExample) |
| HR (1) | HRP20210361T1 (enExample) |
| HU (1) | HUE053671T2 (enExample) |
| LT (1) | LT3094616T (enExample) |
| PL (1) | PL3094616T3 (enExample) |
| PT (1) | PT3094616T (enExample) |
| RS (1) | RS61611B1 (enExample) |
| SI (1) | SI3094616T1 (enExample) |
| SM (1) | SMT202100074T1 (enExample) |
| WO (1) | WO2015109215A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3691630A4 (en) * | 2017-10-06 | 2021-10-27 | Rush University Medical Center | USE OF A COMPOSITION CONTAINING BENZOATE TO TREAT GLYCINE ENCEPHALOPATHY |
| AU2018371628B2 (en) | 2017-11-22 | 2021-08-12 | Excelsior Pharmatech Labs | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression |
| EA202192199A1 (ru) * | 2019-02-25 | 2021-12-17 | Раш Юниверсити Медикал Сентер | Композиции, содержащие коричную кислоту, и способы их применения |
| KR20220066253A (ko) * | 2019-07-16 | 2022-05-24 | 러쉬 유니버시티 메디컬 센터 | 신경퇴행성 장애를 치료하기 위한 벤조에이트 함유 조성물의 용도 |
| WO2022093922A1 (en) | 2020-10-28 | 2022-05-05 | Rush University Medical Center | Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders |
| EP4262781A4 (en) * | 2020-12-16 | 2025-02-12 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| US20250057793A1 (en) * | 2021-12-16 | 2025-02-20 | The United States Government As Represented By The Department Of Veterans Affairs | Benzoic acid salts for treatment of nervous system injuries and disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US20080171792A1 (en) * | 2006-12-28 | 2008-07-17 | Jobdevairakkam Christopher New | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders |
-
2015
- 2015-01-16 HU HUE15737329A patent/HUE053671T2/hu unknown
- 2015-01-16 PT PT157373291T patent/PT3094616T/pt unknown
- 2015-01-16 LT LTEP15737329.1T patent/LT3094616T/lt unknown
- 2015-01-16 PL PL15737329T patent/PL3094616T3/pl unknown
- 2015-01-16 ES ES15737329T patent/ES2853974T3/es active Active
- 2015-01-16 SI SI201531511T patent/SI3094616T1/sl unknown
- 2015-01-16 US US15/110,702 patent/US9968582B2/en active Active
- 2015-01-16 HR HRP20210361TT patent/HRP20210361T1/hr unknown
- 2015-01-16 JP JP2016565117A patent/JP6836905B2/ja active Active
- 2015-01-16 CA CA2936548A patent/CA2936548C/en active Active
- 2015-01-16 SM SM20210074T patent/SMT202100074T1/it unknown
- 2015-01-16 WO PCT/US2015/011798 patent/WO2015109215A1/en not_active Ceased
- 2015-01-16 EP EP15737329.1A patent/EP3094616B1/en active Active
- 2015-01-16 RS RS20210230A patent/RS61611B1/sr unknown
- 2015-01-16 DK DK15737329.1T patent/DK3094616T3/da active
-
2019
- 2019-10-18 JP JP2019191224A patent/JP2020037558A/ja active Pending
-
2021
- 2021-03-09 CY CY20211100204T patent/CY1124115T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3094616T3 (da) | 2021-02-15 |
| ES2853974T3 (es) | 2021-09-20 |
| CA2936548A1 (en) | 2015-07-23 |
| SI3094616T1 (sl) | 2021-07-30 |
| CY1124115T1 (el) | 2022-05-27 |
| CA2936548C (en) | 2022-08-30 |
| JP6836905B2 (ja) | 2021-03-03 |
| LT3094616T (lt) | 2021-04-12 |
| PL3094616T3 (pl) | 2021-05-31 |
| RS61611B1 (sr) | 2021-04-29 |
| JP2017505811A (ja) | 2017-02-23 |
| SMT202100074T1 (it) | 2021-05-07 |
| US9968582B2 (en) | 2018-05-15 |
| EP3094616B1 (en) | 2020-12-23 |
| WO2015109215A1 (en) | 2015-07-23 |
| HUE053671T2 (hu) | 2021-07-28 |
| JP2020037558A (ja) | 2020-03-12 |
| US20160331714A1 (en) | 2016-11-17 |
| EP3094616A1 (en) | 2016-11-23 |
| EP3094616A4 (en) | 2017-08-23 |
| PT3094616T (pt) | 2021-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015057451A5 (enExample) | ||
| MX355065B (es) | Método y dispositivo para conmutación de cámaras. | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| DOP2016000156A (es) | Composiciones farmacã¿uticas que comprenden azd9291. | |
| TN2017000226A1 (en) | New substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs | |
| MX2014011946A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
| JP2015038135A5 (enExample) | ||
| EA201491484A1 (ru) | Фармацевтические композиции, содержащие диметилфумарат | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| JP2016535786A5 (enExample) | ||
| WO2014058979A3 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| JP2017505811A5 (enExample) | ||
| MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
| FI3445351T3 (fi) | Asetyylileusiini tai sen farmaseuttisesti hyväksyttävä suola liikkuvuuden parantamiseen | |
| HRP20192235T1 (hr) | SPOJEVI KORISNI ZA INHIBITIRANJE ROR-γ-T | |
| WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EP2676665A4 (en) | USE OF ALPHA-MANGOSTINE IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF ALZHEIMER | |
| RU2016131454A (ru) | Применения витамина d и его композиций для антибиоза | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| PE20151424A1 (es) | Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| FI3831385T3 (fi) | Pirlindolienantiomeerien mandelaattisuoloja käytettäviksi lääkinnässä | |
| WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) |